AXNX big range break today for the recent IPO, $435M maker of sacral neuromodulation solutions for overactive bladders and urinary retention. AXNX presented positive data this morning and will report on 3-5. It is an early-stage med-tech Co. with $6.9M in revenues seen for 2019 but forecasts calling for $200M+ by 2022.